MannKind Gets FDA Clearance for Clofazimine IND Application
By Chris Wack
MannKind said the Food and Drug Administration has cleared its Investigational New Drug application for MNKD-101 Clofazimine inhalation suspension, enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial lung disease.
The company said it expects to get this study underway by end of the second quarter 2024 in the U.S., and internationally in the second half of 2024.
The study is a randomized, double-blind trial to evaluate the efficacy and safety of Clofazimine inhalation suspension when added to guideline-based therapy in adults with refractory nontuberculous mycobacterial lung disease caused by mycobacterium avium complex.
MannKind said that in 2022, there were about 122,000 patients living with nontuberculous mycobacterial in the U.S.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 29, 2024 06:35 ET (10:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks